CLOs on the Move

Astellas Pharma

www.astellas.us

 
Astellas Pharma US, Inc., a U.S. affiliate of Tokyo-based Astellas Pharma Inc., is a pharmaceutical company dedicated to changing tomorrow by improving the health of people around the world through innovative and reliable pharmaceutical products. In 2005, Astellas was formed by blending the talents, resources and passions of two highly successful firms - Yamanouchi and Fujisawa. Astellas aims to maintain and strengthen our position as the global leader in transplantation and urology areas, and going forward we are working to establish our position as a global category leader in oncology. At all levels throughout the company our people are committed ...
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion
  • www.astellas.us
  • 1 Astellas Way
    Northbrook, IL USA 60062
  • Phone: 800.888.7704

Executives

Name Title Contact Details
Michael Mayes
 Executive Director, Anti-Bribery and Anti-Corruption, Third Party and Distributor Compliance Lead Profile

Similar Companies

Chemica Technologies Inc

Chemica Technologies Inc is a Beaverton, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Focus Express Mail Pharmacy Inc

Focus Express Mail Pharmacy Inc is a Horsham, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

The Harvard Drug Group

The Harvard Drug Group is a Livonia, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

EMD Electronics

Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and performance materials.

Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address large market opportunities, initially in ophthalmic conditions, where there are limited treatment alternatives. It is advancing its pipeline to address several diseases across therapeutic categories including eye care, dermatology, and other diseases with high, unmet needs. Its lead product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of Demodex blepharitis.